NO20080357L - Farmasoytiske sammensetninger for modifisert avgivelse, samt fremgangsmater for fremstilling av samme - Google Patents
Farmasoytiske sammensetninger for modifisert avgivelse, samt fremgangsmater for fremstilling av sammeInfo
- Publication number
- NO20080357L NO20080357L NO20080357A NO20080357A NO20080357L NO 20080357 L NO20080357 L NO 20080357L NO 20080357 A NO20080357 A NO 20080357A NO 20080357 A NO20080357 A NO 20080357A NO 20080357 L NO20080357 L NO 20080357L
- Authority
- NO
- Norway
- Prior art keywords
- preparing
- methods
- pharmaceutical compositions
- well
- same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
Det beskrives nye modifiserte farmasøytiske sammensetninger omfattende i det minste ett aktivt middel; et polymersystem i en mengde mindre enn ca. 80% vekt/vekt av sammensetningen omfattende i det minste to svellbare pH-uavhengige polymerer hvor minst en er hydrofil; og valgfritt andre farmasøytisk akseptable eksipienter. Fremgangsmåter for fremstilling av slike sammensetninger, og anvendelse av disse er også beskrevet. Sammensetningene formuleres til egnete doseringsformer som tilveiebringer terapeutiske konsentrasjoner av aktivt middel for forlengete tidsperioder.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1681DE2005 | 2005-06-29 | ||
PCT/IN2006/000224 WO2007000778A2 (en) | 2005-06-29 | 2006-06-29 | Modified release pharmaceutical compositions on the basis of two polymers and processes thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20080357L true NO20080357L (no) | 2008-03-31 |
Family
ID=37487532
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20080357A NO20080357L (no) | 2005-06-29 | 2008-01-17 | Farmasoytiske sammensetninger for modifisert avgivelse, samt fremgangsmater for fremstilling av samme |
Country Status (14)
Country | Link |
---|---|
US (1) | US20090099151A1 (no) |
EP (1) | EP1906932A2 (no) |
JP (1) | JP2009500317A (no) |
CN (1) | CN101212958A (no) |
AR (1) | AR057422A1 (no) |
AU (1) | AU2006263337A1 (no) |
BR (1) | BRPI0612594A2 (no) |
CA (1) | CA2613403A1 (no) |
CR (1) | CR9704A (no) |
EA (1) | EA200800161A1 (no) |
MX (1) | MX2008000099A (no) |
NO (1) | NO20080357L (no) |
RS (1) | RS20070511A (no) |
WO (1) | WO2007000778A2 (no) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101426478A (zh) * | 2006-02-24 | 2009-05-06 | 特瓦制药工业有限公司 | 氟伐他汀钠药物组合物 |
AU2008258596B2 (en) | 2007-06-04 | 2013-02-14 | Egalet Ltd | Controlled release pharmaceutical compositions for prolonged effect |
WO2008152598A1 (en) * | 2007-06-11 | 2008-12-18 | Ranbaxy Laboratories Limited | Stabilized pharmaceutical compositions comprising atorvastatin |
WO2009019599A2 (en) | 2007-08-08 | 2009-02-12 | Themis Laboratories Private Limited | Extended release compositions comprising tolterodine |
US20110052648A1 (en) * | 2008-03-12 | 2011-03-03 | Avi Avramoff | Oral modified-release formulations containing thiazepines |
ZA200903854B (en) * | 2008-06-19 | 2011-02-23 | Univ Of The Witwatesrand Johannesburg | A gastroretentive pharmaceutical dosage form |
AU2009265099A1 (en) | 2008-07-01 | 2010-01-07 | Lupin Limited | Sustained release pharmaceutical compositions comprising Quetiapine |
JP2012505203A (ja) * | 2008-10-08 | 2012-03-01 | バイオプラス ライフ サイエンスズ ピーヴイティ リミテッド | 持続放出性薬剤送達システム |
US8815971B2 (en) | 2008-12-22 | 2014-08-26 | ATRP Solutions, Inc. | Control over controlled radical polymerization processes |
US8822610B2 (en) | 2008-12-22 | 2014-09-02 | ATRP Solutions, Inc. | Control over controlled radical polymerization processes |
WO2010089259A2 (en) | 2009-02-04 | 2010-08-12 | Woerwag R&D Gmbh | Sustained release composition containing quetiapine |
AU2010211220B2 (en) | 2009-02-06 | 2013-08-01 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
US8173750B2 (en) | 2009-04-23 | 2012-05-08 | ATRP Solutions, Inc. | Star macromolecules for personal and home care |
US9783628B2 (en) | 2009-04-23 | 2017-10-10 | ATRP Solutions, Inc. | Dual-mechanism thickening agents for hydraulic fracturing fluids |
WO2010123574A1 (en) | 2009-04-23 | 2010-10-28 | Atrp Solutions Inc | Star macromolecules for personal and home care |
NZ603579A (en) | 2009-06-24 | 2014-02-28 | Egalet Ltd | Controlled release formulations |
EP2540318B1 (en) | 2010-02-22 | 2018-10-24 | Daiichi Sankyo Company, Limited | Sustained-release solid preparation for oral use |
ES2600894T3 (es) * | 2010-02-22 | 2017-02-13 | Daiichi Sankyo Company, Limited | Preparación sólida de liberación sostenida para uso oral |
CN102281881A (zh) * | 2010-02-26 | 2011-12-14 | 上海沪美医药科技有限公司 | 一种含有喹硫平的控(缓)释制剂及其制备方法和用途 |
DE102010033527A1 (de) | 2010-08-05 | 2012-02-09 | Acino Pharma Ag | Quetiapin-Tabletten |
WO2012060847A1 (en) * | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
KR20120055313A (ko) * | 2010-11-23 | 2012-05-31 | 주식회사 바이오파마티스 | 레베티라세탐 또는 이의 약학적으로 허용되는 염을 포함하는 용출 안정성이 개선된 서방형 약학 조성물 및 이의 제조방법 |
US9587064B2 (en) | 2010-12-08 | 2017-03-07 | ATRP Solutions, Inc. | Salt-tolerant star macromolecules |
DE102011115690A1 (de) | 2011-10-11 | 2013-04-11 | Acino Pharma Ag | Quetiapin enthaltende Formulierungen |
MX368683B (es) | 2012-08-30 | 2019-10-11 | Pilot Polymer Tech Inc | Agentes espesantes de mecanismo dual para fluidos de fracturación hidráulica. |
BR112015004190A2 (pt) | 2012-09-03 | 2017-07-04 | Daiichi Sankyo Co Ltd | composição farmacêutica de liberação sustentada, e, método para produzir uma composição farmacêutica de liberação sustentada |
CN105263978B (zh) | 2013-02-04 | 2018-04-17 | Atrp解决方案公司 | 耐盐星形大分子 |
CN103705933A (zh) * | 2013-12-18 | 2014-04-09 | 北京科源创欣科技有限公司 | 奥卡西平药物组合物及制备方法 |
JP6689210B2 (ja) | 2014-07-03 | 2020-04-28 | パイロット ポリマー テクノロジーズ, インク. | 界面活性剤相溶性星形高分子 |
US20200113839A1 (en) * | 2017-05-02 | 2020-04-16 | Lubrizol Advanced Materials, Inc. | Extended Release Highly Loaded Drug Compositions |
JP7499021B2 (ja) | 2019-12-23 | 2024-06-13 | 小林製薬株式会社 | 経口組成物 |
JP7486311B2 (ja) | 2019-12-23 | 2024-05-17 | 小林製薬株式会社 | 血中コレステロール低下用組成物 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5472711A (en) * | 1992-07-30 | 1995-12-05 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
MX9801835A (es) * | 1996-07-08 | 1998-08-30 | Mendell Co Inc Edward | Matriz de liberacion sostenida para medicamentos insolubles de dosis altas. |
US5972389A (en) * | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
US6056977A (en) * | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
US5916595A (en) * | 1997-12-12 | 1999-06-29 | Andrx Pharmaceutials, Inc. | HMG co-reductase inhibitor |
US6150410A (en) * | 1999-02-04 | 2000-11-21 | Abbott Laboratories | pH independent extended release pharmaceutical formulation |
WO2002041876A1 (en) * | 2000-11-22 | 2002-05-30 | Lupin Limited | Pharmaceutical composition for controlled release of an active ingredient |
CA2481091A1 (en) * | 2002-04-05 | 2003-10-23 | Penwest Pharmaceuticals Co. | Sustained release metoprolol formulations |
-
2006
- 2006-06-29 WO PCT/IN2006/000224 patent/WO2007000778A2/en active Application Filing
- 2006-06-29 BR BRPI0612594-8A patent/BRPI0612594A2/pt not_active IP Right Cessation
- 2006-06-29 US US11/922,961 patent/US20090099151A1/en not_active Abandoned
- 2006-06-29 AR ARP060102821A patent/AR057422A1/es not_active Application Discontinuation
- 2006-06-29 CA CA002613403A patent/CA2613403A1/en not_active Abandoned
- 2006-06-29 EP EP06766277A patent/EP1906932A2/en not_active Withdrawn
- 2006-06-29 RS RSP-2007/0511A patent/RS20070511A/sr unknown
- 2006-06-29 CN CNA2006800239980A patent/CN101212958A/zh active Pending
- 2006-06-29 EA EA200800161A patent/EA200800161A1/ru unknown
- 2006-06-29 JP JP2008519141A patent/JP2009500317A/ja not_active Withdrawn
- 2006-06-29 AU AU2006263337A patent/AU2006263337A1/en not_active Abandoned
- 2006-06-29 MX MX2008000099A patent/MX2008000099A/es unknown
-
2008
- 2008-01-17 NO NO20080357A patent/NO20080357L/no not_active Application Discontinuation
- 2008-01-29 CR CR9704A patent/CR9704A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CR9704A (es) | 2008-07-18 |
AU2006263337A2 (en) | 2008-06-05 |
CA2613403A1 (en) | 2007-01-04 |
WO2007000778A2 (en) | 2007-01-04 |
JP2009500317A (ja) | 2009-01-08 |
CN101212958A (zh) | 2008-07-02 |
MX2008000099A (es) | 2008-03-19 |
US20090099151A1 (en) | 2009-04-16 |
AR057422A1 (es) | 2007-12-05 |
WO2007000778A3 (en) | 2007-03-29 |
EA200800161A1 (ru) | 2008-06-30 |
BRPI0612594A2 (pt) | 2010-11-23 |
EP1906932A2 (en) | 2008-04-09 |
AU2006263337A1 (en) | 2007-01-04 |
RS20070511A (en) | 2009-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20080357L (no) | Farmasoytiske sammensetninger for modifisert avgivelse, samt fremgangsmater for fremstilling av samme | |
NO20062504L (no) | Sammensetninger og doseringsformer for forbedret absorpsjon | |
DE602005013244D1 (de) | Pharmazeutische zusammensetzungen für die kontroll | |
ATE515949T1 (de) | Süssware | |
ATE418324T1 (de) | Mucoadhäsive xyloglucan-haltige formulierung für medizinprodukte und pharmazeutische darreichungsformen | |
RS52813B (en) | PHARMACEUTICAL DOSAGE FORMS | |
ATE493973T1 (de) | Irbesartan enthaltende pharmazeutische zusammensetzung | |
MX2007008141A (es) | Composicion farmaceutica de sustancias labiles en medio acido. | |
SE0401345D0 (sv) | Therapeutic compounds: Pyridine as scaffold | |
TW200503775A (en) | Pharmaceutical composition and method for treating | |
SE0401342D0 (sv) | Therapeutic compounds | |
AR061166A1 (es) | Composiciones farmaceuticas para la liberacion sostenida de fenilferina | |
SE0302573D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
AU2020278236A8 (en) | Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor | |
NO20055601L (no) | Farmasoytisk preparat i form av en hydrogel for transdermal administrasjon av aktive virkestoffer | |
CO5580741A2 (es) | Composicion farmaceutica que comprende un agonista de receptor de 5ht1 | |
SE0302570D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
SE0302572D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
RS51578B (en) | SOLID PHARMACEUTICAL COMPOSITION CONTAINING TELITROMYCIN | |
ATE411311T1 (de) | Tetrahydropyranverbindungen als tachykininantagonisten | |
RU2013102263A (ru) | Гелевые лекарственные формы для местного применения производных 1-аминоалкилциклогексана | |
EA200701525A1 (ru) | Фармацевтическая полимерная композиция для перорального введения тербуталина сульфата с контролируемым высвобождением | |
JP2007277233A (ja) | 眼科用組成物 | |
BR0316123A (pt) | Formulação farmacêutica aquosa, uso de uma formulação farmacêutica aquosa, e, método de tratamento de um paciente com necessidade de tratamento antitrombótico | |
BRPI0506710A (pt) | composições farmacêuticas de liberação controlada |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |